CD4 T-cell and Lymphocyte Monitoring: Clinical Significance in HIV Treatment

EP: 1.HIV Viral Suppression: Clinical Significance and Impact on Patient Outcomes

EP: 2.Changing Patient Demographics in HIV and Impacts of Polypharmacy on Treatment

EP: 3.Phase 3 HIV Treatment Switch Studies: Key Findings From Recent Clinical Trials

EP: 4.HIV Therapy Without Integrase Inhibitor: Practical Advantages and Targeted Patient Populations

EP: 5.Long-Acting HIV Therapies: Real-World Data and Clinical Application

Now Viewing

EP: 6.CD4 T-cell and Lymphocyte Monitoring: Clinical Significance in HIV Treatment

EP: 7.CROI 2025 Insights: Evolving HIV Treatment Landscape and Practice-Changing Developments

CD4 T-Cell Monitoring in HIV Management

Key Themes:

• Immune Reconstitution: Average CD4 count increases of approximately 200 cells in the first year of effective therapy
• Laboratory Variability: CD4 count fluctuations of up to 20% between measurements, causing potential patient concern
• Clinical Utility Debate: Discussion of whether routine CD4 monitoring remains necessary in stable patients
• Toxicity Monitoring: Importance of CD4 count monitoring in trials of new agents with potential lymphotoxicity

Notable Insights from Dr Sharon Walmsley:

• Despite some recommendations to reduce CD4 monitoring (“choosing wisely” initiatives), many patients value these numbers as reinforcement that treatment is working.
• CD4 counts remain important for guiding opportunistic infection prophylaxis decisions in patients with lower values.
• CD4 monitoring can serve as a motivational tool for patients struggling with adherence.
• In switch studies, CD4 counts typically remain stable when patients are already virologically suppressed.